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AD: Atopic dermatitis
AHR: Airway hyperresponsiveness
BALF: Bronchoalveolar lavage fluid
CD: Crohn disease
cNK: Classical natural killer
CRTH2: Chemoattractant receptor-homologous molecule expressed
on TH2 cells
EGID: Eosinophilic gastrointestinal disorder
EoE: Eosinophilic esophagitis
GWAS: Genome-wide association study
HDM: House dust mite
IBD: Inflammatory bowel disease
ILC: Innate lymphoid cell
ILC1: Group 1 innate lymphoid cell
ILC2: Group 2 innate lymphoid cell
ILC3: Group 3 innate lymphoid cell
KLRG1: Killer cell lectin-like receptor G1
LTD4: Leukotriene D4
LTi: Lymphoid tissue inducer
NCR: Natural cytotoxicity receptor
NK: Natural killer
OVA: Ovalbumin
PGD2: Prostaglandin D2
RORgt: Retinoic acid–related orphan receptor gt
STAT: Signal transducer and activator of transcription
T-bet: T-box transcription factor
Treg: Regulatory T
TSLP: Thymic stromal lymphopoietin
UC: Ulcerative colitisIn the last decade, the full picture of the role of innate lymphoid cells
(ILCs) has been gradually revealed. ILCs are classified into 3
groupsbasedon their transcription factorsandcytokineproduction
patterns, which mirror helper T-cell subsets. Unlike T cells and
B cells, ILCs do not have antigen receptors. They promptly respond
to multiple tissue-derived factors, such as cytokines and alarmins,
and produce multiple proinflammatory and immunoregulatory
cytokines. It has been reported that ILC-derived cytokines are
important for the induction and regulation of inflammation.
Accumulating evidence suggests that ILCs play substantial roles in
protection against infection and the pathogenesis of inflammatory
diseases, such as allergic diseases and autoimmune diseases.
Different ILC subsets localize in distinct tissue/organ niches and
receive tissue-derived signals on different types of inflammation,
which allows them to acquire diverse phenotypes with specialized
effector capacities. In this review we highlight the roles of ILCs in a
variety of organs, such as the airway, skin, and gastrointestinal
tract, in the context of allergic and nonallergic inflammation. (J
Allergy Clin Immunol 2016;138:1253-64.)
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Innate lymphoid cells (ILCs) are recently identified immune
cells that have lymphoidmorphology but lack an antigen receptor.
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WAT: White adipose tissuecell-derived factors, such as cytokines and eicosanoids, which are
produced by other cells in response to pathogen-associated mo-
lecular patterns and damage-associated molecular patterns,
leading to their designation as innate immune cells. ILCs develop
from common lymphoid progenitors in fetal liver and bone
marrow and are dependent on common g chain receptor
signaling and the transcription factor Id2.1-3 They have been clas-
sified into 3 different subpopulations, namely group 1 innate
lymphoid cells (ILC1s), group 2 innate lymphoid cells (ILC2s),
and group 3 innate lymphoid cells (ILC3), which resemble TH
cell subsets, according to their distinct patterns of cytokine pro-
duction and transcription factors (Fig 1).4
ILC1s, which resemble TH1 cells, are defined by production of
the type 1 cytokine IFN-g and expression of T-box transcription
factor (T-bet) and have been implicated in immunity against
intracellular pathogens, such as viruses and intracellular1253
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1254 MORITA, MORO, AND KOYASUbacteria.3,5,6 Group 1 ILCs include 2 different populations: clas-
sical natural killer (cNK) cells and ILC1s. Both cNK cells and
ILC1s produce IFN-g on activation with IL-12, IL-15, and IL-
18. The cytotoxic activity of cNK cells is mediated by the produc-
tion of granzymes and perforin similar to CD81 cytotoxic
T cells,7 whereas ILC1s do not produce granzymes or perforin.
Although cNK cells develop from Id21 progenitors, which have
the potential to develop into all ILC subsets, ILC1s develop
from a PLZFhigh ILC progenitor that has lost the potential to
develop into either cNK cells or lymphoid tissue inducer (LTi)
cells, a type of ILC3.
ILC2s, which are phenotypically similar to TH2 cells, are
defined by the production of the type 2 cytokines IL-4, IL-5,
IL-9, and IL-13 and expression of GATA-3.8-15 Although
GATA-3 has been reported to be indispensable for the develop-
ment of all IL-7 receptor a1 ILC subsets (ILC1s, ILC2s, and
ILC3s), excluding cNK cells,16,17 it is a functional requirement
for the development of ILC2s. The designation ILC2 collectively
refers to natural helper cells and nuocytes (inflammatory ILC2s).
Although natural helper cells exist in diverse tissues in the steady
state, nuocytes or inflammatory ILC2s are induced in IL-25–
mediated inflammation. ILC2s can be activated by various cyto-
kines, such as IL-33, IL-25, thymic stromal lymphopoietin
(TSLP),8-11 and IL-1b,18,19 as well as eicosanoids, such as pros-
taglandin D2 (PGD2)
20 and leukotriene D4 (LTD4).
21 ILC2s also
produce amphiregulin, a member of the epidermal growth factor
family, on activation.22 Therefore ILC2s have been implicated in
immunity against helminths, allergic diseases, and tissue repair.
ILC3s, which resemble TH17 cells, are defined by the production
of IL-17A and IL-22 and by expression of retinoic acid–related
orphan receptor gt (RORgt) and have been implicated in immunity
against extracellular bacteria and autoimmune diseases.4 ILC3sGLOSSARY
CHITIN: Also known as poly-N-acetyl-D-glucosamine, a polysaccharide
found in the cell wall of fungi and the integument of insects and
crustaceans. Its structure is similar to cellulose. It is used in the pesticide
industry as a fertilizer that deters soil nematode growth. Intra-airway
administration of chitin induces asthma-like airway inflammation in
mice.
COMMON g CHAIN: A signal-transducing chain for multiple type I
cytokine receptors (IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21), also known as
CD132. Janus kinase 3 (JAK3) is used for common g chain signaling.
Common g chain mutations are the cause of X-linked severe combined
immunodeficiency (X-SCID). Autosomal recessive mutations in the
JAK3 gene result in a similar phenotype as X-SCID.
DAMAGE-ASSOCIATED MOLECULAR PATTERNS (DAMPs): Molecules
produced by cell damage caused by infection, toxins, burns, trauma, or
hypoperfusion. Alarmins are a specific DAMP produced to enhance the
innate immune response to infection. Other examples include heat
shock protein and monosodium urate.
EICOSANOIDS: Arachidonic acid–derived compounds that act as in-
flammatory mediators. Examples include prostaglandins and leukotri-
enes. The term is based on the Greek word eikosi, which means 20 (the
number of carbon atoms in arachidonic acid).
IMIQUIMOD: A Toll-like receptor 7 ligand used as a pharmaceutical
topical product for the treatment of condyloma acuminata, actinic
keratosis, and superficial basal cell carcinoma. Topical application of
imiquimod induces psoriasis-like skin inflammation in mice.
The Editors wish to acknowledge Daniel Searing, MD, for preparing this glocomprise 3 different populations: LTi cells,23,24 natural cytotoxicity
receptor (NCR)1 ILC3s, and NCR2 ILC3s. LTi cells express
CCR6 and produce IL-17A, IL-17F and IL-22 on activation with
IL-1b and IL-23. They have heterogeneous expression of CD4
and are a source of lymphotoxin, which is necessary for the forma-
tion of secondary lymphoid tissues.23,24 NCR1 ILC3s and NCR2
ILC3s are distinguished by the expression of NCRs, such as
NKp44 in human subjects and NKp46 in mice. Both cell popula-
tions produce IL-22 on activation by IL-1b and IL-23,4,25-31 but
NCR1 ILC3s are strong producers of IFN-g.
Interestingly, ILCs display functional plasticity in response to
environmental cues, which enables them to respond promptly to
environmental changes. For instance, conversion between ILC1s
and ILC3s30 and ILC1s and ILC2s18,19,32,33 has been reported in
human subjects. In brief, ILC3s differentiate into ILC1s on IL-12
stimulation, followed by T-bet induction, whereas ILC1s revert to
ILC3s on stimulation with IL-23, IL-1b, and retinoic acid, which
are found in the intestine in patients with Crohn disease (CD).30 In
addition, ILC2s differentiate into ILC1s on IL-12 stimulation, fol-
lowed by T-bet induction, whereas ILC1s revert to ILC2s on stim-
ulation with IL-4, which is found in the lungs in patients with
chronic obstructive pulmonary disease and in nasal tissue in pa-
tients with chronic rhinosinusitis with nasal polyps.18,19,32,33
These findings suggest that ILCs might receive specific tissue-
derived signals in response to different types of inflammation
and subsequently acquire diverse phenotypes with specialized
effector capacities.ILCs IN ALLERGIC AIRWAY INFLAMMATION
A recent genome-wide association study (GWAS) showed that
genetic polymorphisms in the gene encoding IL-33, which is aLAMINA PROPRIA: A layer of themucusmembrane that lies beneath the
epithelium and contains connective tissue, lymphocytes,mast cells, and
plasma cells.
PAPAIN: A cysteine protease present in papaya fruit. One of its main
uses in the food industry is as a meat-tenderizing agent. Intra-airway
administration of papain induces asthma-like airway inflammation in
mice.
RECOMBINATION-ACTIVATING GENE (Rag): A lymphoid-specific gene
that produces protein critical for V(D)J recombination. Rag stands for
recombination-activating gene and includes Rag1 and Rag2 proteins.
Rag1 or Rag2 deficiency leads to the deficiency of T, B, andNKT cells and
results in severe combined immunodeficiency.
STEROID-RESISTANT ASTHMA: Often defined in the literature as an
adult asthmatic patient whose FEV1 percent predicted does not improve
by 10% to 12% after a course of 20 mg of prednisone twice daily for
7 days.
T-box TRANSCRIPTION FACTOR (T-bet): Amember of the T-box family
of transcription factors that is encoded by the gene Tbx21 and activated
by IFN-g. Its induction in CD41 T cells then stimulates additional IFN-g
production, resulting in a positive amplification loop for TH1
differentiation.
THYMIC STROMAL LYMPHOPOIETIN: A cytokine secreted by gastroin-
testinal, skin, and lung epithelial cells that promotes a TH2 differential
through its effect on tissue dendritic cells and ILC2s. Its name arises
from its initial identification in thymic stromal cells.
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FIG 1. Effector subsets of ILCs. ILCs are divided into 3 different subsets based on their different transcription
factors and cytokine expression. ILC1s produce type 1 cytokines, such as IFN-g, on stimulation with IL-12, IL-
15, and IL-18 and express T-bet. These cells are involved in immune responses against intracellular
pathogens and act in chronic inflammation. Group 2 ILCs produce type 2 cytokines, such as IL-4, IL-5, IL-9,
and IL-13, on stimulation with epithelium-derived cytokines, such as IL-33, IL-25, TSLP, eicosanoids, and IL-
1b. These cells are involved in immune responses against helminths or fungi and induce allergic
inflammation. ILC3s produce type 3 cytokines, such as IL-17A and IL-22, in response to IL-1b and IL-23
stimulation. These cells play an important role in defense against extracellular pathogens and chronic
inflammation. Areg, Amphiregulin; Eomes, eomesodermin.
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MORITA, MORO, AND KOYASU 1255major activator of ILC2s, and its receptor IL-1RL1 (ST2) are
strongly linked to asthma development.34,35 Although the genes
that encode IL-33 and IL-1RL1 are located on different chromo-
somes, these 2 genes have consistently been identified in many re-
ports, strongly suggesting that the IL-33–IL-1RL1 pathway and
ILC2s are involved in asthma pathogenesis.36 Indeed, in human
subjects a recent study showed that the frequency of ILC2s, as
defined by the expression of chemoattractant receptor-
homologous molecule expressed on TH2 cells (CRTH2), IL-7 re-
ceptor in peripheral blood37-39 and bronchoalveolar lavage fluid
(BALF),39-41 and IL-33 levels in BALF,40 were increased in
asthmatic patients compared with control subjects. Moreover,
the frequency of ILC2s in peripheral blood38 and BALF,40 as
well as IL-33 levels in BALF,40 were negatively correlated with
airway function, indicating that ILC2s and IL-33 are involved
in asthma pathogenesis.
A recent study showed that ILC2s are involved in eosinophilic
asthma–like airway inflammation, including eosinophilinfiltration, airway hyperresponsiveness (AHR), and mucus pro-
duction, even in the absence of acquired immunity, such as
T cells, B cells, and IgE antibody.42-44 In addition, in mice inha-
lation of epithelium-derived cytokines, such as IL-33 and IL-25,
induces eosinophilic asthma–like airway inflammation accompa-
nied by AHR, even in recombination-activating gene (Rag)2/2
mice, which lack T cells, B cells, and natural killer (NK)
T cells.42-46 In contrast, IL-33–induced airway inflammation
was diminished inRag22/2Il2rg2/2mice, which lack all lympho-
cytes, including ILCs, but was restored to some extent by engraft-
ment of ILC2s.42 These findings clearly show that ILC2s induce
eosinophilic airway inflammation independent of acquired immu-
nity on activation by epithelium-derived cytokines, such as IL-33
and IL-25 (Fig 2). It has been shown recently that many asthma-
related antigens, such as protease allergens, fungal extracts, and
viral infection, trigger IL-33 and IL-25 production from epithelial
cells and various immune cells and induce eosinophilic asthma–
like airway inflammation through activation of lung ILC2s
FIG 2. Roles of ILCs in allergic and nonallergic airway inflammation. In patients with allergic airway
inflammation, protease allergens, such as HDM, and fungal and viral infection induce IL-33, IL-25, and TSLP
from epithelial cells and macrophages. These cytokines induce production of type 2 cytokines, such as IL-5
and IL-13, from ILC2s, which leads to eosinophilic inflammation, even in the absence of acquired immunity.
PGD2 and LTD4 from mast cells also induce type 2 cytokines from ILC2s, and basophil-derived IL-4 and
inducible costimulator (ICOS)/ICOS ligand interaction on ILC2s are important for ILC2 activation. IL-5
from ILC2s promotes accumulation of eosinophils, and IL-13 induces goblet cell hyperplasia and accumu-
lation of alveolar macrophages. ILC2s also activate TH2 cells through OX40 ligand (OX40L) andMHC class II.
IFN-a/b, IFN-g, IL-27, prostaglandin I2 (PGI2), and Treg cells suppress ILC2 activation and attenuate ILC2-
mediated airway inflammation. In patients with nonallergic airway inflammation, such as obesity-
associated asthma, IL-1b derived from macrophages induces IL-17A production by ILC3s, which results in
induction of neutrophils and AHR. Macrophage-derived IL-1b can also activate ILC2s and enhance airway
inflammation. Areg, Amphiregulin.
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allergens, such as house dust mites (HDMs), cockroaches, fungi,
and pollens were reported to possess protease activities.50
Although protease activities of allergens destroy epithelial cells,
which enables the allergen to cross the tissue barrier, resulting
in allergen sensitization, these protease activities also induce
IL-33 release from epithelial cells, which induces asthma-like
airway inflammation through ILC2 activation. In fact, papain,
which is homologous to the HDM allergen Der 1 and used in
the food industry, is known to be a cause of occupational
asthma.51 Administration of papain to mice induces IL-33 secre-
tion from lung epithelial cells and induces eosinophilic asthma–
like airway inflammation through activation of lung ILC2s by
IL-33.42,44,47,52 Under these conditions, it was shown that
basophil-derived IL-453 and inducible costimulator/inducible
costimulator ligand interaction on ILC2s54 play important roles
in the activation of lung ILC2s. However, mast cells activated
by IL-33 play a protective role by expanding regulatory T
(Treg) cells that suppress ILC2 activation (Fig 2).42,55
Administration of Alternaria species, a major fungal aeroaller-
gen, also induces eosinophilic airway inflammation in micethrough activation of lung ILC2s by IL-33 and IL-25.21,47,48 In
agreement with this, it was shown that IL-33 expression was
increased in sinonasal epithelial cells from patients with chronic
rhinosinusitis with nasal polyps on stimulation with fungal extracts
from Alternaria alternata, Aspergillus fumigatus, and Cladospo-
rium herbarum.56 Chitin, a key structural component of fungi,
HDM, and helminths, is also known to induce eosinophilic airway
inflammation independent of acquired immunity.57Recently, itwas
shown that ILC2s activated by IL-33, IL-25, and TSLPare essential
for the induction of chitin-induced eosinophilic airway inflamma-
tion through type 2 cytokine production.58
Viral infection also induces asthma-like airway inflammation
through activation of ILC2s independent of acquired immunity.
For example, it was shown that H3N1 influenza Avirus infection
induced AHR through activation of lung ILC2s by alveolar
macrophage–derived IL-33.49 In addition, respiratory syncytial
virus infection induced AHR and mucus accumulation through
activation of lung ILC2s by epithelium-derived TSLP but not
IL-33.59,60 Rhinovirus infection of neonatal mice induced long-
term mucus metaplasia and AHR through activation of lung
ILC2s by epithelium-derived IL-25.61 Interestingly, unlike
J ALLERGY CLIN IMMUNOL
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accumulation were not observed in adult mice infected by rhino-
virus,61 suggesting that early-life rhinovirus infection might
contribute to the development of asthma later through activation
of lung ILC2s, which results in chronic mucus metaplasia and
AHR. In support of this notion, a recent epidemiologic study
showed that wheezing episodes on viral respiratory tract infec-
tions, such as rhinovirus and respiratory syncytial virus in early
life, are strongly associated with asthma development.62 Taken
together, activation of ILC2s by IL-33, IL-25, and TSLP induced
by allergens and viruses is crucial for initiation of asthma-like
airway inflammation development before antigen sensitization.
ILC2s contribute not only to the initiation of innate allergic
airway inflammation but also to the enhancement of allergic
inflammation by interacting with other immune cells. The role of
ILC2s in acquired immunity was analyzed in mouse models that
require a sensitization phase before the challenge phase, such as
HDM, ovalbumin (OVA), and papain exposure models. In an
HDM model and papain exposure model, eosinophilic airway
inflammation was attenuated in mice that were lethally irradiated
and transplanted with bone marrow cells from Rorasg/sg mice.
Because Rora is critical for ILC2 differentiation, these mice
lack ILC2s (ILC2-deficient mice). T-cell responses to antigen
were significantly decreased in ILC2-deficient mice compared
with control mice.63,64 ILC2s have been reported to have a direct
effect on TH2 cell activation through OX40 ligand
65 and MHC
class II66 on ILC2s in vitro. In addition, ILC2s have also been re-
ported to have an indirect effect on memory TH2 cell recruitment
through induction of CCL17 from dendritic cells.67 These mech-
anisms might be involved in the activation of acquired immunity
(Fig 2). In contrast, in an OVAmodel eosinophilic airway inflam-
mation was comparable between ILC2-deficient mice and control
mice.63 Whereas HDM and papain exposure model mice were
sensitized by intranasal antigen administration, OVA model
mice were sensitized by systemic antigen administration. There-
fore it is possible that ILC2s have crucial roles in the initiation of
local immune responses to antigen but not in the initiation of sys-
temic immune responses.
In human lungs ILC2s are located in proximity to mast cells,68
suggesting that ILC2s can also interact with mast cells. CRTH2, a
distinctive marker on human ILC2s, is a receptor for PGD2 that is
produced by activated mast cells. It was shown that PGD2 induces
migration of human ILC2s through CRTH220,69 and induces type
2 cytokine production from human ILC2s.20,68 Another lipid
mediator, LTD4, derived from mast cells was also shown to acti-
vate ILC2s in mice. LTD4 induces type 2 cytokine production
from mouse ILC2s and accumulation of lung ILC2s in Alternaria
species–induced eosinophilic inflammation.21 PGD2 and LTD4
are released by mast cells on degranulation induced by IgE
cross-linking.70,71 Therefore these findings suggest that mast cells
activated on IgE cross-linking contributes to enhancement of
allergic airway inflammation through recruitment and activation
of ILC2s. In contrast, IL-33 induces IL-2 production from mast
cells that promotes Treg cell expansion42 but not degranulation
of mast cells.72,73 Therefore mast cells activated by IL-33
contribute to the regulation of allergic airway inflammation
through suppression of ILC2s by Treg cells (Fig 2).
Recent studies suggest that ILC2s also have important roles in
steroid-resistant severe allergic airway inflammation and persis-
tence of chronic airway inflammation.39,43 In human subjects it
was shown that the number of total ILC2s and type 2 cytokine–producing ILC2s in peripheral blood and sputum were signifi-
cantly increased in patients with systemic steroid-dependent se-
vere eosinophilic asthma compared with those with mild
asthma. In contrast, the number of type 2 cytokine–producing
CD41 T cells did not differ significantly between these 2 patient
groups.39 These findings suggest that ILC2s, but not CD41
T cells, play a significant role in steroid-resistant asthma and pro-
mote the development of airway inflammation in patients with
systemic steroid-dependent severe eosinophilic asthma. Like-
wise, corticosteroids suppressed TH2 cells, but not ILC2s, in an
OVA-induced asthma model when a low dose of IL-33 was coad-
ministered with OVA, which results in corticosteroid-resistant
airway inflammation. In this model TSLP was shown to be a
key molecule that induces corticosteroid resistance of ILC2s by
controlling phosphorylation of signal transducer and activator
of transcription (STAT) 5 and expression of Bcl-xL. Furthermore,
STAT5 inhibitors abrogated steroid resistance in this model.43
It is known that symptoms persist in most patients with
occupational asthma, even years after removal of exposure to
the occupational antigen.74 However, little is known about the
mechanisms regulating these persistent symptoms. It was recently
shown that ILC2s, but not T cells, play a pivotal role in the persis-
tence of asthma. Three allergens (ie, HDM, ragweed, and Asper-
gillus species) induced persistent allergic inflammation in mice,
which exhibited persistent inflammation and AHR for more
than 6 months after cessation of allergen exposure. In these
models depletion of T cells reduced sustained airway inflamma-
tion to some extent but did not eliminate sustained AHR. In
contrast, depletion of ILC2s completely eliminated sustained
airway inflammation and AHR, indicating the importance of
ILC2s in the persistence of chronic asthma.40
Taken together, ILC2s play a pivotal role in the initiation,
enhancement, and steroid resistance of allergic airway inflam-
mation. Consequently, regulation of ILC2 activation is likely an
important target to control asthma. Recently, IFN-a/b,75,76 IFN-
g,75-77 IL-27,75,76,78 Treg cells,42 and prostaglandin I2,
79 were
shown to suppress ILC2 activation in vitro and in vivo (Fig 2).
These findings open a new window for the prevention and treat-
ment of asthma.ILCs IN NONALLERGIC AIRWAY INFLAMMATION
Although asthma has been considered a single disease for
years, recent studies indicate that asthma is actually a heteroge-
neous disease composed of different phenotypes, such as allergic
asthma, including early-onset allergic asthma and late-onset
persistent eosinophilic asthma, and nonallergic asthma, including
neutrophilic asthma and obesity-related asthma.80 As mentioned
before, evidence has accumulated that ILC2s are involved in
allergic-type asthma. However, the role of ILCs in nonallergic
asthma remains unclear. Obesity has been suggested to play a sub-
stantial role in the development of asthma.81 Recent findings sug-
gest that ILCs are also involved in obesity-associated allergic
airway inflammation. The numbers of ILC3s in the lungs of
high-fat diet–fed obese mice was increased compared with those
in standard diet–fed mice. In addition, AHR was induced in high-
fat diet–fed obese mice in the absence of an antigen challenge.
This obesity-induced AHR is independent of acquired immunity
but dependent on IL-17A. Obesity-inducedAHRwas ameliorated
in Rag22/2Il2rg2/2 mice, which lack all ILCs in addition to
T cells, B cells, and NKT cells, and adoptive transfer of ILC3s
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suggesting that IL-17A–producing ILC3s play a critical role in
obesity-induced AHR. Under these conditions, IL-1b produced
by macrophages on activation of the nucleotide-binding domain,
leucine-rich repeat/pyrin domain-containing 3 pathway induces
IL-17A production from ILC3s (Fig 2).82
It has recently been shown that obesity contributes to airway
inflammation not only through activation of ILC3s but also
through ILC2 activation. ILC2 numbers in the lungs of high-fat
diet–fed obese mice were also increased compared with those in
low-fat diet–fed mice without antigen challenge. On HDM
administration, airway inflammation and AHR accompanied by
accumulation of ILC2s and ILC3s were exacerbated in high-fat
diet–fed obese mice compared with mice fed a standard diet,
suggesting that activation of both ILC2s and ILC3s plays an
important role in obesity-associated airway inflammation on
HDM challenge.83 Although the mechanisms for ILC2 activation
in high-fat diet–fed obese mice have not been clarified, a recent
study showed that IL-1b also activates ILC2s to produce type 2
cytokines,18,19 suggesting that IL-1b signaling is a possiblemech-
anism underlying obesity-induced ILC2 activation (Fig 2).
Interestingly, unlike in the lungs, it was shown that ILC2
responses in white adipose tissue (WAT) were dysregulated in
obese patients. Because the IL-33/ILC2 axis regulates metabolic
homeostasis by eliciting beiging of WAT, dysregulation of ILC2s
in WAT might be one possible mechanism of obesity.84 However,
the mechanisms that induce dysregulation of ILC2 responses in
WAT remain unclear.
Of note, ILC2s promote beneficial tissue repair responses in
the lung after acute epithelial damage, such as viral infection. It
has been reported that depletion of ILC2s during H1N1 influenza
infection impaired lung function and epithelial integrity, which
were restored after adoptive transfer of lung ILC2s or admin-
istration of amphiregulin, suggesting that ILC2s contribute to
lung tissue repair through amphiregulin production (Fig 2).22
However, as mentioned before, by using a different H3N1 influ-
enza virus, another article showed that ILC2s could be patho-
genic during influenza virus infection through IL-13
production.49 These findings suggest that the roles of ILC2s in
the lungs during viral respiratory tract infection might be
different depending on the level of tissue damage, types of virus,
and environmental factors. Further studies are needed to fully
characterize the different roles of ILC2s in the lungs during viral
respiratory tract infection.ILCs IN ALLERGIC SKIN INFLAMMATION
Atopic dermatitis (AD) is the most common chronic and
relapsing inflammatory skin disease characterized by type 2–
skewed inflammation and epithelial barrier dysfunction.85
Expression of TSLP,86 IL-25,87 and IL-33,88 which activate
ILC2s, was upregulated in lesional skin from patients with AD
compared with healthy skin, suggesting that ILC2s play a crucial
role in the pathogenesis of AD through activation by these cyto-
kines. Indeed, it has been shown that ILC2s are resident in healthy
skin tissue in both human subjects and mice,89,90 and the fre-
quency of ILC2s was higher in skin tissue from lesional skin of
human patients with AD compared with that in healthy sub-
jects.89,90 The responsiveness of skin ILC2s to epithelium-
derived cytokines is still controversial. Salimi et al90 reported
that ILC2s isolated from healthy skin produced type 2 cytokineson stimulation by IL-33 but not IL-25 and TSLP. Conversely, Teu-
nissen et al91 reported that ILC2s from healthy skin samples pro-
duced type 2 cytokines on TSLP, but not IL-33 and IL-25,
stimulation. However, IL-17RB (IL-25 receptor), ST2 (IL-33 re-
ceptor), TSLP receptor, and CRTH2 were highly upregulated on
ILC2s from human AD skin lesions compared with ILC2s from
healthy skin,90 suggesting that ILC2s in AD skin lesions are high-
ly activated and more responsive to stimuli, such as IL-25, IL-33,
TSLP, and PGD2 (Fig 3). The role of ILC2s in allergic skin inflam-
mation has also been investigated by using different mouse
models. Overexpression of IL-3392 and TSLP93,94 in the skin
spontaneously induces AD-like skin inflammation accompanied
by itching, eosinophil infiltration, and thickening of the
epidermis. In particular, numbers of Lin2ST21Sca-11 skin
ILC2s were increased in lesional skin from transgenic mice
with skin-specific expression of IL-33, indicating involvement
of the IL-33–ILC2 axis in this model.92 Topical treatment with
a vitamin D analog, calcipotriol, was also shown to induce AD-
like skin inflammation accompanied by eosinophil infiltration,
epidermal hyperplasia, and increased type 2 cytokine produc-
tion.89 Similarly, a vitamin D analog also induced AD-like skin
inflammation in Rag12/2 mice, which lack acquired immunity,
but depletion of ILCs by an anti-CD25 antibody attenuated skin
inflammation, suggesting that ILCs, but not T cells, B cells, and
NKT cells, are critical in this model.89 It is unknown whether
similar mechanisms mediate skin inflammation in the above-
mentioned mouse models.
Furthermore, the involvement of epithelium-derived cytokines,
such as IL-33 and TSLP, in these models is controversial.
Kim et al89 demonstrated that skin inflammation was attenuated
in Tslpr2/2 mice, but not in Il332/2 mice, compared with
wild-type mice on a C57BL/6 background. In contrast, Salimi
et al90 demonstrated that skin inflammation was attenuated in
Il17rb2/2 mice and St22/2 mice, but not Tslpr2/2 mice, on a
BALB/c background. These differences might be due to
differences in genetic backgrounds and environmental factors,
including microbiota.
Interactions of ILC2s with other cell types have also been
shown to be critical in the pathogenesis of allergic skin
inflammation. Basophils, which are usually undetectable in
healthy control skin, were enriched in the dermis of human AD
lesions in close proximity to ILC2s,95 suggesting that the interac-
tion between ILC2s and basophils is involved in the pathogenesis
of AD. Indeed, depletion of basophils attenuated vitamin D
analog–induced AD-like skin inflammation in mice. Moreover,
conditional depletion of IL-4 in basophils also attenuated vitamin
D analog–induced AD-like skin inflammation and accumulation
of ILC2s in the skin.95 Therefore it is likely that basophils play
a critical role in the initiation of allergic skin inflammation
through activation of skin ILC2s by means of production of
IL-4 (Fig 3). Mast cells also accumulated in the lesional skin in
human and mouse AD models,96 suggesting that the interaction
between mast cells and ILC2s is also involved in the pathogenesis
of AD. Indeed, it has been shown that PGD2 promotes the migra-
tion of skin ILC2s and induces type 2 cytokine production from
skin ILC2s. Moreover, the supernatant of IgE/anti-IgE–activated
mast cells also induces migration and cytokine production by hu-
man skin ILC2s.20 Because mast cells produce PGD2 bymeans of
activation through FcεRI, they likely play a role in migration and
cytokine production by ILC2s through the effects of PGD2 (Fig
3). Killer cell lectin–like receptor G1 (KLRG1), which is known
FIG 3. Role of ILCs in allergic and nonallergic skin inflammation. In patients with allergic skin inflammation,
such as AD, epithelial cell–derived cytokines, such as IL-33, IL-25, and TSLP, induce type 2 cytokine
production from ILC2s. ILC2s from AD lesional skin express IL-17RB (IL-25 receptor), ST2 (IL-33 receptor),
TSLP receptor, and CRTH2. Basophils and mast cells accumulate in the lesional skin of patients with AD.
Similar to what is observed in patients with allergic airway inflammation, basophil-derived IL-4 is important
for ILC2 activation. Mast cell–derived PGD2 induces type 2 cytokine production from ILC2s. E-cadherin ex-
pressed on keratinocytes and Langerhans cells suppresses ILC2 activation by means of ligation to KLRG1
on ILC2s. Decreased expression of E-cadherin in keratinocytes from patients with AD results in persistent
activation of ILC2s. In patients with nonallergic skin inflammation, such as psoriasis, IL-22 from NCR1
ILC3s induces skin thickening, and IL-17A from ILC3s induces neutrophil infiltration. ILC3s accumulate in
wound sites through Notch1 and contribute to wound healing through IL-17F, IL-17A, and IL-22.
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ILC2s in mice.97 KLRG1 binds to the cell adhesion molecule E-
cadherin, which is expressed on keratinocytes and Langerhans
cells.98 KLRG1was highly expressed on skin ILC2s from patients
with AD comparedwith skin ILC2s from healthy control subjects,
and TSLP and IL-33, but not IL-25, upregulated KLRG1 expres-
sion on cultured ILC2s. In addition, E-cadherin ligation to
KLRG1 on ILC2s suppressed cytokine production from skin
ILC2s,90 suggesting that the KLRG1–E-cadherin interaction
plays an important role in the negative feedback mechanisms in
activated skin ILC2s (Fig 3). Interestingly, E-cadherin expression
was decreased in keratinocytes from AD lesional skin compared
with that seen in normal skin.99 In addition, E-cadherin was
downregulated in keratinocytes on short hairpin RNA knockdown
of the filaggrin gene that has crucial roles in skin barrier func-
tion.90 These findings suggest that low E-cadherin expression
on keratinocytes in patients with AD leads to persistent activation
of ILC2s in AD skin lesions.
Taken together, ILC2s are likely involved in the induction of
allergic skin inflammation through activation by epithelium-
derived cytokines, such as IL-33, IL-25, and TSLP, and interac-
tion with other immune cells.ILCs IN NONALLERGIC SKIN INFLAMMATION
Psoriasis is a common chronic skin inflammatory disease
characterized by epidermal thickness and scaly plaques that
affects approximately 2% of the population.100 Previously, T cells
and dendritic cells were considered to play key roles in the path-
ogenesis of psoriasis through production of cytokines, such as IL-
17A, IL-17F, and IL-22. In brief, IL-17A and IL-17F contribute to
disease pathogenesis by inducing neutrophilic inflammation, and
IL-22 contributes to epidermal hyperplasia (Fig 3).101 However,
recent studies have shown that ILCs, particularly ILC3s that pro-
duce IL-17A and IL-22, also play substantial roles in the patho-
genesis of psoriasis. The frequency of NCR1 ILC3s, but not
ILC1s or ILC2s, was increased in peripheral blood from patients
with psoriasis compared with healthy control subjects.91,102
Moreover, the frequency of NCR1 ILC3s was increased in le-
sional91 and nonlesional103 skin from patients with psoriasis
compared with healthy skin. Importantly, the frequency of
NCR1 ILC3s in the skin correlated with disease severity deter-
mined by the Psoriasis Area and Severity Index.91 In addition,
the frequency of NCR1 ILC3s in peripheral blood was decreased
on anti-TNF antibody treatment and was closely associated with
the reduction of disease severity determined by using the Psoriasis
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with psoriasis can produce IL-22 and, to a lesser extent, IL-
17A,91,102 suggesting that ILC3s have a pathogenic role in psori-
asis through IL-22 and, to a lesser extent, IL-17A production.
In mice topical application of imiquimod induces skin
inflammation accompanied by acanthosis and plaque formation
that largely resembles the disease phenotype of human psoriasis.
In this model gd T cells and ILC3s, but not TH17 cells, were the
main source of these cytokines. Indeed, imiquimod-induced skin
inflammation was induced in Rag12/2mice, which lack acquired
immunity, but was completely diminished in Rag22/2Il2rg2/2
mice, which lack ILCs, and Rorgt2/2 mice, which lack
TH17 cells and ILC3s.
104 Taken together, these findings suggest
that ILC3s have critical roles as effector cells in the development
of psoriasis-like skin inflammation in mice through production of
IL-17A, IL-17F, and IL-22 (Fig 3).
ILC3s have also been shown to play a substantial role in skin
repair. It was shown that RORgt1 ILC3s were recruited to wound
sites through epidermal Notch1 signaling in mice. Similarly
RORgt1 ILC3s infiltrated human skin after wounding by using
a punch biopsy. In addition, wound healing was delayed in
mice deficient for RORgt1 ILC3s accompanied by delayed
epidermal proliferation and macrophage recruitment.105 Interest-
ingly, themajority of mouse ILC3s that accumulated in thewound
site expressed IL-17F but lower amounts of IL-17A and IL-22.
Likewise, human ILC3s accumulating in the wound site ex-
pressed IL-17F and IL-17A.105 These findings suggest that
ILC3s contribute to repair of skin tissue through production of
IL-17F and, to a lesser extent, IL-17A and IL-22 (Fig 3).ILCs IN ALLERGIC GASTROINTESTINAL
INFLAMMATION
Primary eosinophilic gastrointestinal disorders (EGIDs),
including eosinophilic esophagitis (EoE), eosinophilic gastritis,
eosinophilic gastroenteritis, and eosinophilic colitis, are disorders
that exhibit eosinophil-rich inflammation in the gastrointestinal
tract in the absence of known causes for eosinophilia such as
parasite infection and drug reaction.106,107 Although food-
specific IgE antibodies were detected in the serum of patients
with EGIDs, typical symptoms observed in patients with IgE-
dependent food allergy, such as anaphylaxis, were not induced
in patients with EGIDs. Therefore EGIDs were considered to be
independent of IgE antibodies but dependent on IL-51IL-131
TH2 cell activation by antigens.
106 However, recent findings sug-
gest the involvement of ILC2s in the pathogenesis of EGIDs.
EoE is a chronic, antigen-mediated disease characterized by
eosinophil infiltration, esophageal remodeling, subepithelial
fibrosis, and smooth muscle dysmotility. Although type 2
cytokines, such as IL-5 and IL-13, were shown to be involved
in its pathogenesis,108,109 the cellular sources of these cytokines
were not well clarified. Results from GWASs suggest that the
TSLP gene is associated with EoE.110 Indeed, TSLP expression
was increased in esophageal biopsy specimens from patients
with active EoE compared with control subjects.110,111 In addi-
tion, expression of IL-33 and IL-25 was increased in the esoph-
agus, and the frequency of ILC2s was increased in esophageal
biopsy specimens from patients with active EoE compared with
those with inactive EoE and control subjects. Importantly, the fre-
quency of ILC2s correlated with the number of eosinophils in
esophageal biopsy samples from patients with EoE.112 Thesefindings strongly suggest that ILC2s have a pathogenic role in pa-
tients with EoE through type 2 cytokine production induced by
TSLP, IL-33, and IL-25 (Fig 4).
The involvement of ILCs in patients with other types of EGIDs
remains unclear. However, it was shown that TSLP and IL-33
expression in sigmoid colon biopsy specimens was increased in
patients with eosinophilic gastroenteritis,113 suggesting that
ILC2s are also involved in other types of EGIDs.ILCs IN NONALLERGIC GASTROINTESTINAL
INFLAMMATION
Inflammatory bowel diseases (IBDs), such asCDand ulcerative
colitis (UC), are a group of chronic disorders of the gastrointes-
tinal tract characterized by intestinal inflammation and epithelial
injury.114 GWASs have identified several IBD susceptibility loci
that contain genes encoding cytokines and cytokine receptor
signaling. These loci contain genes related to type 1 immune re-
sponses, such as those encoding IFN-g and IL-12 receptor and
its intracellular signaling components, such as STAT1 and
STAT4, as well as genes related to type 3 immune responses,
such as those encoding IL-23 receptor and its intracellular
signaling components, such as STAT3.115 These findings suggest
that type 1 and type 3 cytokines are involved in the pathogenesis of
IBD. Indeed, various studies showed that production of the type 1
cytokine IFN-g by lamina propria TH1 cells was increased in pa-
tients with CD compared with healthy control subjects but not in
patients with UC.116,117 In addition, production of type 3 cyto-
kines, such as IL-17A and IL-17F, by lamina propria TH17 cells
was increased in patients with CD, as well as in patients with
UC.117,118 ILCs also produce type 1 and type 3 cytokines similar
to T cells, but their involvement in IBD in vivo is largely unknown.
The frequency of ILC1s in noninflamed intestine was reported to
be approximately 10% of total ILCs but increased to 40% in
inflamed intestines of patients with CD.5,30 In human subjects it was
shown that there are 2 distinctive subtypes of ILC1s, namely
CD1271 ILC1s located in the lamina propria5,30 and
CD1031CD1272 ILC1s located in the epithelium.6 Both popula-
tions produce IFN-g on IL-12 stimulation in synergy with IL-15
and IL-18. Whereas the frequencies of CD1271 ILC1s and
CD1031CD1272 ILC1swere comparable in noninflamed intestinal
tissue, the frequency of CD1271 ILC1s, but not CD1031CD1272
ILC1s, was significantly increased in inflamed intestinal tissues
from patients with CD.30 These findings suggest that ILC1s play a
role in the pathogenesis of CD through IFN-g production (Fig 4).
ILC2s were also detected in intestinal tissue from patients with
CD. Interestingly, unlike ILC2s in peripheral blood, ILC2s in
intestinal tissue from patients with CD produce IFN-g in addition
to IL-13.32 These findings suggest that ILC2s in intestinal tissue
from patients with CD might have received environmental cues,
which enable them to convert to ILC1s.
ILC3s comprise the majority of ILCs (NCR1 ILC3s, 70%;
NCR2 ILC3s, 15%) in noninflamed human intestine.5,30
Although the frequency of NCR2 ILC3s in inflamed intestine
from patients with CD was comparable with that in noninflamed
control intestinal tissue, the frequency of NCR1 ILC3s was
dramatically (70% / 20%) decreased in inflamed intestine
from patients with CD.5,119 Intestinal NCR1 ILC3s produce IL-
22 in response to IL-23 in synergy with IL-1b.5,120 In addition, in-
testinal CD141 macrophages promote IL-22 production from
NCR1 ILC3s through IL-23 and direct interaction (Fig 4).31
FIG 4. Roles of ILCs in allergic and nonallergic gastrointestinal inflammation. In patients with allergic
gastrointestinal inflammation, such as EoE, epithelium-derived cytokines, such as IL-33, IL-25, and TSLP,
induce type 2 cytokine production from ILC2s and induce eosinophil infiltration. In patients with nonallergic
gastrointestinal inflammation, such as IBD, ILC1s contribute to disease pathogenesis through IFN-g
production. Macrophage-derived IL-23 induces IL-22 production from NCR1 ILC3s, which is important for
intestinal barrier function, wound healing, and antimicrobial production. Decreased frequency of NCR1
ILC3s might unfavorably affect the pathogenesis of CD. NCR2 ILC3s produce IL-17A together with IL-22.
However, the role of IL-17A in human IBD is not clear. ILC3s also have protective roles in the intestine.
ILC3s induce cell death in TH17 cells through MHC class II. In addition, ILC3s produce GM-CSF, which acti-
vates macrophages to generate Treg cells by retinoic acid and TGF-b.
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epithelial cells, and IL-22 mediates intestinal epithelial barrier
maintenance and wound healing31,121,122 and provides functional
barrier support by inducing antimicrobials, such as Reg family
molecules and S110 proteins.123 These findings suggest that IL-
22 is important for protection against the bacterial infection and
tissue injury that occur in patients with IBD. Indeed, in mice
ILC3s were an essential source of IL-22 that protected against
dextran sodium sulfate–induced colitis, in which the epithelial
barrier was disrupted.124,125 Thus NCR1 ILC3s might play a pro-
tective role in the pathogenesis of IBD through IL-22 production
in humans, and the decrease of IL-22–producing NCR1 ILC3s is
unfavorable for patients with IBD (Fig 4). Intriguingly, however,
IL-22 was also pathogenic in certain mouse models that mimic
human IBD.126 Further investigation is needed to clarify the roles
of IL-22–producing NCR1 ILC3s in patients with IBD.
Another subset of ILC3s, NCR2 ILC3s, have also been
described in the human intestine. Human intestinal NCR2
ILC3s from patients with CD produce IL-17A and IL-17F and,
to a lesser extent, IL-22 on IL-23 stimulation.5,127 However, the
role of NCR2 ILC3s in patients with IBD remains unclear. In
mice IL-17A–producing NCR2 ILC3s were indispensable for
the pathogenesis of mouse colitis models that resemble humanIBD, such as Helicobacter hepaticus–induced colitis128 and
microbiota-dependent colitis in Tbx212/2Rag22/2 mice, which
lack T-bet in the innate immune system.129 Anti–IL-17A treat-
ment attenuated intestinal inflammation in these models, suggest-
ing the importance of IL-17A–producing NCR2 ILC3s in the
induction of inflammation in these mice. In contrast to mouse
models, the frequency of NCR2 ILC3s in inflamed tissues from
patients with CD was comparable with that in noninflamed con-
trol tissue.30 In addition, inhibition of IL-17A by the anti–IL-
17A antibody secukinumab was ineffective in a clinical trial of
patients with moderate-to-severe CD.130 These findings suggest
that NCR2 ILC3s and IL-17A likely do not play a critical role
in human CD.
ILC3s were also shown to have a regulatory role in the intestine
through interaction with other immune cell subsets, such as
macrophages and T cells. It was shown that on IL-1b stimulation,
ILC3-derived GM-CSF drives retinoic acid and TGF-b
production from macrophages to generate Treg cells that limit
intestinal inflammation (Fig 4).131 MHC class II is expressed on
NCR2 ILC3s in both human subjects and mice. MHC class II1
NCR2 ILC3s suppress the response of CD41 T cells to
commensal bacteria by inducing cell death. Moreover,
depletion of MHC class II1 ILC3s in mice results in commensal
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activation.132,133 These findings suggest that MHC class II1
NCR2 ILC3s are important for the maintenance of intestinal ho-
meostasis by limiting bacteria-induced T-cell activation through
MHC class II (Fig 4). Interestingly, the expression level of
MHC class II on intestinal ILC3s from patients with pediatric
CD was significantly lower than that on ILC3s in the intestines
of control subjects. In addition, the expression level of MHC class
II on ILC3s in the intestines of patients with pediatric CD nega-
tively correlated with the frequency of TH17 cells.
133 These find-
ings suggest that alteration of MHC class II expression on ILC3s
is one of the mechanisms that controls the frequency of patho-
genic TH17 cells.
Taken together, NCR2 ILC3s can have both protective and
pathogenic roles in patients with IBD, and further studies are
needed to clarify these roles.CONCLUDING REMARKS
Before the discovery of ILCs, T cells were considered the main
cell type responsible for the pathogenesis of inflammatory
disease. However, recent studies have shown that ILCs are also
essential players in many inflammatory diseases. It is now clear
that ILCs play critical roles not only in the initiation of
inflammation but also in chronic inflammation and resolution of
inflammation through interactions with tissue cells and other
immune cells. Further studies are needed to reveal the entire
picture of interaction between various cell types and clarify the
roles of ILCs in different types of inflammation. Findings from
these studies could potentially lead to the development of new
therapies for inflammatory diseases that target ILC activation
pathways.
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